Skip to main content
Erschienen in: Clinical Pharmacokinetics 7/2006

01.07.2006 | Original Research Article

Comparison of Oxycodone Pharmacokinetics after Buccal and Sublingual Administration in Children

verfasst von: Dr Hannu Kokki, Ilpo Rasanen, Merja Lasalmi, Sanna Lehtola, Veli-Pekka Ranta, Kari Vanamo, Ilkka Ojanperä

Erschienen in: Clinical Pharmacokinetics | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective

We evaluated and compared the pharmacokinetics of two oral administration routes of oxycodone parenteral liquid (10 mg/mL) - single buccal and sublingual administration - in 30 generally healthy awake children, aged 6–91 months.

Methods

Two groups of children undergoing inpatient surgery were enrolled. In a randomised fashion, children received a single dose of oxycodone 0.2 mg/kg buccally (n = 15) or sublingually (n = 15). Regular blood samples were collected for up to 12 hours, and plasma was analysed for oxycodone, oxymorphone and noroxycodone using gas chromatography-mass spectrometry.

Results

Bioavailability was similar after administration at the two instillation sites. The area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC) was 2400–8000 ng · min/mL (median 4200 ng · min/mL) in the buccal group and 2700-7900 ng · min/mL (median 5500 ng · min/mL) in the sublingual group. After buccal administration, maximum plasma concentration (Cmax) was 5.4–39 ng/mL (16 ng/mL) after buccal and 5.5–42 ng/mL (22 ng/mL) after sublingual administration. Twelve of the 15 children in both groups reached the oxycodone analgesic concentration of 12 ng/mL, which was sustained for 43–209 minutes (median 160 minutes) in the children with buccal oxycodone and for 32–262 minutes (median 175 minutes) in the children with sublingual oxycodone. The terminal elimination half-lives were closely similar in the two groups: 104–251 minutes (median 140 minutes) in the buccal group and 110–190 minutes (150 minutes) in the sublingual group.

Conclusion

The results of this study show that in young children the absorption of oxycodone is similar after buccal and sublingual instillation.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005; 59: 674–6PubMedCrossRef Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005; 59: 674–6PubMedCrossRef
2.
Zurück zum Zitat Freund M, Speyer E. Uber die Umwandlung von Thebain in Oxycodeinon und dessen Derivate. J Prak Chemie 1916; 153/94: 135–78CrossRef Freund M, Speyer E. Uber die Umwandlung von Thebain in Oxycodeinon und dessen Derivate. J Prak Chemie 1916; 153/94: 135–78CrossRef
3.
Zurück zum Zitat Falk E. Eukodal. Ein neues Narkotikum. Munch Med Wochenschr 1917; 20: 381–4 Falk E. Eukodal. Ein neues Narkotikum. Munch Med Wochenschr 1917; 20: 381–4
5.
Zurück zum Zitat Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1: 15–30PubMed Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1: 15–30PubMed
6.
Zurück zum Zitat Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992; 81: 1–10PubMedCrossRef Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 1992; 81: 1–10PubMedCrossRef
7.
Zurück zum Zitat Kokki H, Rasanen I, Reinikainen M, et al. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 2004; 43: 613–22PubMedCrossRef Kokki H, Rasanen I, Reinikainen M, et al. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 2004; 43: 613–22PubMedCrossRef
8.
Zurück zum Zitat Kokki H, Lintula H, Vanamo K, et al. Oxycodone vs placebo in children with undifferentiated abdominal pain: a randomized, double-blind clinical trial of the effect of analgesia on diagnostic accuracy. Arch Pediatr Adolesc Med 2005; 159: 320–5PubMedCrossRef Kokki H, Lintula H, Vanamo K, et al. Oxycodone vs placebo in children with undifferentiated abdominal pain: a randomized, double-blind clinical trial of the effect of analgesia on diagnostic accuracy. Arch Pediatr Adolesc Med 2005; 159: 320–5PubMedCrossRef
9.
Zurück zum Zitat Broussard LA, Presley LC, Pittman T, et al. Simultaneous identification and quantitation of codeine, morphine, hydrocodone, and hydromorphone in urine as trimethylsilyl and oxime derivatives by gas chromatography-mass spectrometry. Clin Chem 1997; 43: 1029–32PubMed Broussard LA, Presley LC, Pittman T, et al. Simultaneous identification and quantitation of codeine, morphine, hydrocodone, and hydromorphone in urine as trimethylsilyl and oxime derivatives by gas chromatography-mass spectrometry. Clin Chem 1997; 43: 1029–32PubMed
10.
Zurück zum Zitat Cremece M, Wu AHB, Gassella G, et al. Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. J Forensic Sci 1998; 43: 1220–4 Cremece M, Wu AHB, Gassella G, et al. Improved GC/MS analysis of opiates with use of oxime-TMS derivatives. J Forensic Sci 1998; 43: 1220–4
11.
Zurück zum Zitat Ropero-Miller JD, Lambing MK, Winecker RE. Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization. J Anal Toxicol 2002; 26: 524–8PubMed Ropero-Miller JD, Lambing MK, Winecker RE. Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization. J Anal Toxicol 2002; 26: 524–8PubMed
12.
Zurück zum Zitat Jones J, Tomlinson K, Moore C. The simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, 6-acetylmorphine, and oxycodone in hair and oral fluid. J Anal Toxicol 2002; 26: 171–5PubMed Jones J, Tomlinson K, Moore C. The simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, 6-acetylmorphine, and oxycodone in hair and oral fluid. J Anal Toxicol 2002; 26: 171–5PubMed
13.
Zurück zum Zitat Huber L. Validation of analytical methods: review and strategy. LC-GC Int 1998; 11: 96–105 Huber L. Validation of analytical methods: review and strategy. LC-GC Int 1998; 11: 96–105
14.
Zurück zum Zitat Tuomilehto H, Kokki H, Ahonen R, et al. Postoperative behavioral changes in children after adenoidectomy. Arch Otolaryngol Head Neck Surg 2002; 128: 1159–64PubMed Tuomilehto H, Kokki H, Ahonen R, et al. Postoperative behavioral changes in children after adenoidectomy. Arch Otolaryngol Head Neck Surg 2002; 128: 1159–64PubMed
15.
Zurück zum Zitat Peters JW, Koot HM, de Boer JB, et al. Major surgery within the first 3 months of life and subsequent biobehavioral pain responses to immunization at later age: a case comparison study. Pediatrics 2003; 111: 129–35PubMedCrossRef Peters JW, Koot HM, de Boer JB, et al. Major surgery within the first 3 months of life and subsequent biobehavioral pain responses to immunization at later age: a case comparison study. Pediatrics 2003; 111: 129–35PubMedCrossRef
16.
Zurück zum Zitat McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 9481: 205–10CrossRef McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 9481: 205–10CrossRef
17.
Zurück zum Zitat Olkkola KT, Hamunen K, Seppälä T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38: 71–6PubMedCrossRef Olkkola KT, Hamunen K, Seppälä T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38: 71–6PubMedCrossRef
18.
Zurück zum Zitat Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44: 335–42PubMedCrossRef Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 44: 335–42PubMedCrossRef
19.
Zurück zum Zitat Takala A, Kaasalainen V, Seppälä T, et al. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 1997; 41: 309–12PubMedCrossRef Takala A, Kaasalainen V, Seppälä T, et al. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 1997; 41: 309–12PubMedCrossRef
20.
Zurück zum Zitat Pokela ML, Anttila E, Seppälä T, et al. Marked variation in oxycodone pharmacokinetics in infants. Paediatr Anaesth 2005; 7: 560–5CrossRef Pokela ML, Anttila E, Seppälä T, et al. Marked variation in oxycodone pharmacokinetics in infants. Paediatr Anaesth 2005; 7: 560–5CrossRef
21.
Zurück zum Zitat Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokineticpharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59: 52–61PubMedCrossRef Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokineticpharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59: 52–61PubMedCrossRef
22.
Zurück zum Zitat Leow KP, Smith MT. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 1994; 54: 1229–36PubMedCrossRef Leow KP, Smith MT. The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 1994; 54: 1229–36PubMedCrossRef
23.
Zurück zum Zitat Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32: 447–54PubMedCrossRef Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32: 447–54PubMedCrossRef
24.
Zurück zum Zitat Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165–71PubMedCrossRef Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165–71PubMedCrossRef
Metadaten
Titel
Comparison of Oxycodone Pharmacokinetics after Buccal and Sublingual Administration in Children
verfasst von
Dr Hannu Kokki
Ilpo Rasanen
Merja Lasalmi
Sanna Lehtola
Veli-Pekka Ranta
Kari Vanamo
Ilkka Ojanperä
Publikationsdatum
01.07.2006
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 7/2006
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200645070-00009

Weitere Artikel der Ausgabe 7/2006

Clinical Pharmacokinetics 7/2006 Zur Ausgabe

Review Article

Tipranavir